Firefly Neuroscience CEO to Present at Global Investment Conference
![Firefly Neuroscience CEO to Present at Global Investment Conference](https://investorshangout.com/images/blog/ihnews-Firefly%20Neuroscience%20CEO%20to%20Present%20at%20Global%20Investment%20Conference.jpg)
Firefly Neuroscience CEO Jon Olsen to Present at Global Conference
Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) firm focused on enhancing brain health outcomes, has announced an upcoming presentation by CEO Jon Olsen at H.C. Wainwright’s 26th Annual Global Investment Conference. This important event will highlight revolutionary advancements within the company, including their FDA-510(k) cleared Brain Network Analytics (BNA™) platform.
Presentation Highlights and Corporate Milestones
During the conference, Mr. Olsen is set to address significant developments, including the recent merger transaction with WaveDancer. The presentation will underline Firefly’s commitment to improving healthcare for patients with neurological and mental health disorders. BNA™ aims to bring objective assessments of brain activity to healthcare professionals, thereby assisting in the diagnosis and treatment of various conditions, including depression, dementia, anxiety disorders, concussions, and ADHD.
H.C. Wainwright Conference Details
Event: H.C. Wainwright’s 26th Annual Global Investment Conference
Date: September 11, 2024
Time: 1:30 p.m. ET
Location: Lotte New York Palace Hotel, New York City
Speaker: Jon Olsen, CEO
Future of Brain Health Technologies
Firefly’s BNA™ technology is the first of its kind, leveraging AI to deliver accurate diagnostics and treatment assessments. This innovative platform, built on a massive database of brain wave tests and clinical data, is designed to empower healthcare providers by offering in-depth insights into brain functionality. Through BNA™, clinicians can make informed decisions regarding patient care, optimizing treatment strategies based on individual needs.
Development and Commercial Launch of BNA™
For over 15 years, Firefly has developed its extensive database, achieving critical IP protections and FDA clearances necessary for the commercial launch of BNA™ technology. The Company is now focusing efforts on partnerships with pharmaceutical companies involved in drug research and clinical trials, as well as medical practitioners for clinical applications.
Company Overview
Firefly Neuroscience is committed to advancing brain health by utilizing cutting-edge AI technologies. The BNA™ platform stands out due to its innovative integration of machine learning with a vast repository of high-definition longitudinal EEG data collected from over 17,000 patients across diverse brain health conditions. This enhances diagnostic accuracy and therapeutic effectiveness.
Importance of Accurate Brain Activity Measurement
Accurate measurement of brain activity is crucial for guiding treatment decisions in mental health care. BNA™ provides clinicians with comprehensive analytical tools, enabling them to determine the most suitable therapies and interventions for their patients effectively.
Contact Information for Investors and Media
For inquiries regarding one-on-one meetings with Mr. Olsen or Dr. Samer Kaba, Chief Medical Officer, stakeholders can reach out through KCSA Strategic Communications. Investor contact is managed by Valter Pinto at KCSA with the phone number (212) 896-1254. Media inquiries should be directed to Raquel Cona at (516) 779-2630.
Frequently Asked Questions
What is the main focus of Firefly Neuroscience?
Firefly Neuroscience focuses on developing AI technologies aimed at improving brain health outcomes for patients with neurological and mental disorders.
What will Jon Olsen discuss at the conference?
Jon Olsen will discuss recent corporate milestones, including the merger with WaveDancer and advancements in the FDA-cleared Brain Network Analytics technology.
When is the H.C. Wainwright Conference?
The H.C. Wainwright’s 26th Annual Global Investment Conference is scheduled for September 9-11, 2024, with Jon Olsen's presentation on September 11 at 1:30 p.m. ET.
How does BNA™ technology benefit clinicians?
BNA™ technology provides comprehensive insights into brain function, helping clinicians in diagnosing mental and cognitive disorders and optimizing patient care.
Who can be contacted for investor relations?
Investors can contact Valter Pinto at KCSA Strategic Communications for any inquiries regarding the company or to schedule meetings with senior executives.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- NMSDC and WEConnect International Unite for MWBE Empowerment
- Boat Hook Market Forecast: Growth to $4.82 Billion
- Multiple Sclerosis Diagnosis and Treatment Market Insights
- Sleep Apnea Devices Market Expected to Hit $14.7 Billion
- i3D Protocol Gains Momentum Ahead of BitMart Listing
- Is Pfizer Stock (NYSE: PFE) A Strong Buy After Setbacks?
- AI Training Dataset Market Set to Reach USD 14.42 Billion
- Electric Three Wheelers Market to Hit $12.15 Billion by 2032
- Herring Global Expands Leadership Team with Key Hires
- Innovative Protein Alternatives for Sustainable Animal Feed